Parabolic Drugs Peer Comparison

NSE: PARABDRUGS | BSE: 533211

₹5.50

₹-0.25 (-4.35%)

As on 25-Jan-2021IST

Market cap

₹35 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

P/B Ratio

-0

Div. Yield

0 %

Edit

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	35	30,075	30,128	28,384	25,980
Revenue (₹ Cr)	--	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-19.98	414.00	288.22	-371.81	387.35
Net Margin (%)	-7,345.96	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	--	73.53	104.53	--	67.27
Price-To-Book	-0.04	5.97	22.44	3.55	15.06

Income Statement (₹ Cr)

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	73.16	3,936.90	65.18	--	188.22
Total Income	77.32	4,114.39	69.48	--	191.18
Total Expenditure	102.22	3,992.33	60.56	--	157.70
EBITDA	-29.06	-55.43	4.63	--	30.52
Depreciation	21.59	149.53	6.27	--	1.91
EBIT	-50.65	-204.96	-1.64	--	28.62
Interest	9.30	255.49	2.16	--	3.23
Other Income	4.16	177.49	4.29	--	2.96
Exceptional Items	--	-358.19	--	--	--
Profit before Tax	-55.79	-641.15	0.49	--	28.35
Provision for Tax	1.76	25.70	0.28	--	9.85
Profit after Tax	-57.55	-666.85	0.21	--	18.50

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	-855.34	2,852.15	178.44	--	57.68
Minority Interest	--	345.73	--	--	--
Non-Current Liabilities	870.07	2,088.89	14.20	--	32.73
Current Liabilities	394.21	2,691.71	34.62	--	65.00
Total Liabilities	408.94	8,127.59	227.25	--	155.45

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	333.03	4,598.88	73.08	--	66.45
Current Assets	73.73	3,379.60	154.17	--	87.20
Total Assets	408.94	8,127.59	227.25	--	155.45
Total Debt*	983.03	3,747.82	29.82	--	43.83
Net Current Assets	-320.49	687.89	119.55	--	22.19
Contingent Liabilities	--	576.12	--	--	--

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	3.07	68.44	-16.11	--	8.46
Cash Flow from Investing Activities	0.86	630.24	19.72	--	-25.32
Cash from Financing Activities	-3.70	-769.47	-2.53	--	14.62
Net Cash Inflow / Outflow	0.23	-70.79	1.08	--	-2.23

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-31.96	-5.47	1.27	--	38.24
ROE (%)	0.00	-21.81	0.12	--	39.03
ROA (%)	-12.89	-7.93	0.09	--	13.99
EBIT Margin (%)	-34.04	3.10	13.68	--	17.79
Net Margin (%)	-74.43	-16.21	0.31	--	9.67
Cash Profit Margin (%)	-49.15	-13.14	9.94	--	10.84

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-2.33	-1.94	0.00	--	17.45
EBIT Growth (%)	65.51	-3.93	-8.67	--	43.40
Net Profit Growth (%)	46.76	-195.01	0.00	--	53.51
EPS Growth (%)	46.76	-210.52	0.00	--	54.05
Book Value Growth (%)	-5.32	-14.68	0.00	--	43.84

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	0.00	0.00	--	0.00
Price / Book Value	-0.05	2.85	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	-41.29	87.67	3.50	--	1.32
Market Cap (₹ Cr)	46.11	8,035.78	0.00	--	0.00

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	-1.11	1.33	0.17	--	0.78
Short term debt to equity ratio	-0.17	0.15	0.08	--	0.16
Current Ratio	0.19	1.26	4.45	--	1.34
Quick Ratio	0.15	0.94	4.05	--	0.92
Interest Coverage	-5.00	-1.51	1.23	--	9.79

	Parabolic Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	39.40	24.45	57.13	--	26.55
Asset Turnover	0.16	0.47	0.29	--	1.42
Receivable days	239.34	92.57	208.51	--	83.83
Inventory Days	77.67	91.03	78.67	--	45.68
Payable days	534.67	115.29	264.75	--	139.26
Cash Conversion Cycle	-217.66	68.30	22.43	--	-9.76

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.